Product Description: Regadenoson (CVT-3146) is a selective A2A adenosine receptor agonist and vasodilator that increases coronary blood flow, can be used in study of myocardial perfusion imaging. Regadenoson also increases the permeability of the blood-brain barrier (BBB) in rodents, can be used to study increased delivery of agents to the human CNS[1][2].
Applications: COVID-19-immunoregulation
Formula: C15H18N8O5
References: [1]Trochu JN, et al. Selective A2A adenosine receptor agonist as a coronary vasodilator in conscious dogs: potential for use in myocardial perfusion imaging. J Cardiovasc Pharmacol. 2003 Jan;41(1):132-9. /[2]Jackson S, et al. The effect of regadenoson-induced transient disruption of the blood-brain barrier on temozolomide delivery to normal rat brain. J Neurooncol. 2016 Feb;126(3):433-9.
CAS Number: 313348-27-5
Molecular Weight: 390.35
Compound Purity: 99.59
Research Area: Cardiovascular Disease; Cancer
Solubility: DMSO : 50 mg/mL (ultrasonic)
Target: Adenosine Receptor
English
Deutsch
